Lv1
8 积分 2021-07-03 加入
The scientific basis of combination therapy for chronic hepatitis B functional cure
16分钟前
待确认
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
3个月前
已完结
Targeting Histone Deacetylase 6 Reprograms Interleukin‐17‐Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma
4个月前
已完结
Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection
6个月前
已完结
Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load
6个月前
已完结
PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis
6个月前
已完结
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B
6个月前
已完结
Dissecting the divergent effects of interferon-alpha on immune cells: Time to rethink combination therapy in chronic hepatitis B?
6个月前
已完结
Engineered IFN-α and anti-PDL1 containing compounds to target the liver and restore antiviral protection for HBV cure
6个月前
已完结
Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load
8个月前
已完结
皖公网安备34019202002308
